SAPHNELOยฎ (anifrolumab-fnia): A First-In-Class IFN-1 Signaling Inhibitor, Now With 4-Year Data From a Long-Term Safety and Tolerability Study
Exhibit Hall, Innovation Theater A
Developed and offered by AstraZeneca
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by AstraZeneca
(Non-CME)
Exhibit Hall, Live Lightning Talks Lounge
Presented by AiArthritis
(Non-CME)
Exhibit Hall, Live Lightning Talks Lounge
Presented by Association of Women in Rheumatology
(Non-CME)
Exhibit Hall, Live Lightning Talks Lounge
Presented by Infinity Care Solutions
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
Exhibit Hall, Live Lightning Talks Lounge
Presented by Sagebrush Health
(Non-CME)
Exhibit Hall, Live Lightning Talks Lounge
Presented by American College of Rheumatology
(Non-CME)
Exhibit Hall, Innovation Theater A
Developed and offered by Sanofi
(Non-CME)
Exhibit Hall, Innovation Theater B
Developed and offered by GSK
(Non-CME)
Hilton San Diego Bayfront, 204 (AB)
Developed and offered by Novartis Pharmaceuticals Corporation
(Non-CME)
Hilton San Diego Bayfront, Sapphire Ballroom A
Developed and offered by GSK
(Non-CME)
Manchester Grand Hyatt, Harbor Ballroom C
Developed and offered by UCB, Inc.
(Non-CME)
Popular Articles